BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28811133)

  • 1. Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors.
    Rondanin R; Fochi S; Baruchello R; Bernardi T; Oliva P; Semeraro F; Simoni D; Giannini G
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4421-4425. PubMed ID: 28811133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of sulfonate and sulfamate derivatives possessing benzofuran or benzothiophene nucleus as inhibitors of nucleotide pyrophosphatases/phosphodiesterases and anticancer agents.
    Anbar HS; El-Gamal R; Ullah S; Zaraei SO; Al-Rashida M; Zaib S; Pelletier J; Sévigny J; Iqbal J; El-Gamal MI
    Bioorg Chem; 2020 Nov; 104():104305. PubMed ID: 33017718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
    Iqbal J; Saeed A; Raza R; Matin A; Hameed A; Furtmann N; Lecka J; Sévigny J; Bajorath J
    Eur J Med Chem; 2013; 70():685-91. PubMed ID: 24215819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel N-acetyl-Glycol-split heparin biotin-conjugates endowed with anti-heparanase activity.
    Esposito E; Vlodavsky I; Barash U; Roscilli G; Milazzo FM; Giannini G; Naggi A
    Eur J Med Chem; 2020 Jan; 186():111831. PubMed ID: 31740052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.
    Jia L; Ma S
    Eur J Med Chem; 2016 Oct; 121():209-220. PubMed ID: 27240275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
    Marchetti D; Reiland J; Erwin B; Roy M
    Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.
    Baburajeev CP; Mohan CD; Rangappa S; Mason DJ; Fuchs JE; Bender A; Barash U; Vlodavsky I; Basappa ; Rangappa KS
    BMC Cancer; 2017 Mar; 17(1):235. PubMed ID: 28359266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, radiolabeling with fluorine-18 and preliminary in vivo evaluation of a heparan sulphate mimetic as potent angiogenesis and heparanase inhibitor for cancer applications.
    Kuhnast B; El Hadri A; Boisgard R; Hinnen F; Richard S; Caravano A; Nancy-Portebois V; Petitou M; Tavitian B; Dollé F
    Org Biomol Chem; 2016 Feb; 14(6):1915-20. PubMed ID: 26757783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and structure-activity relationship of heparanase inhibitors: Recent advances.
    Fu K; Bai Z; Chen L; Ye W; Wang M; Hu J; Liu C; Zhou W
    Eur J Med Chem; 2020 May; 193():112221. PubMed ID: 32222663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New classes of potent heparanase inhibitors from ligand-based virtual screening.
    Pala D; Scalvini L; Elisi GM; Lodola A; Mor M; Spadoni G; Ferrara FF; Pavoni E; Roscilli G; Milazzo FM; Battistuzzi G; Rivara S; Giannini G
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1685-1696. PubMed ID: 32907434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antimetastatic activity of 6-trichloroacetamido and 6-guanidino analogues of siastatin B.
    Satoh T; Nishimura Y; Kondo S; Takeuchi T; Azetaka M; Fukuyasu H; Iizuka Y; Ohuchi S; Shibahara S
    J Antibiot (Tokyo); 1996 Mar; 49(3):321-5. PubMed ID: 8626252
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of heparanase inhibitors in cancer therapy.
    Heyman B; Yang Y
    Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, in vitro antiproliferative activity, and in silico studies of fused tricyclic coumarin sulfonate derivatives.
    El-Gamal MI; Oh CH
    Eur J Med Chem; 2014 Sep; 84():68-76. PubMed ID: 25016229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent.
    Ishida K; Hirai G; Murakami K; Teruya T; Simizu S; Sodeoka M; Osada H
    Mol Cancer Ther; 2004 Sep; 3(9):1069-77. PubMed ID: 15367701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
    Rotili D; De Luca A; Tarantino D; Pezzola S; Forgione M; Morozzo Della Rocca B; Falconi M; Mai A; Caccuri AM
    Eur J Med Chem; 2015 Jan; 89():156-71. PubMed ID: 25462236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendrimer Heparan Sulfate Glycomimetics: Potent Heparanase Inhibitors for Anticancer Therapy.
    Zubkova OV; Ahmed YA; Guimond SE; Noble SL; Miller JH; Alfred Smith RA; Nurcombe V; Tyler PC; Weissmann M; Vlodavsky I; Turnbull JE
    ACS Chem Biol; 2018 Dec; 13(12):3236-3242. PubMed ID: 30480427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity.
    Madia VN; Messore A; Pescatori L; Saccoliti F; Tudino V; De Leo A; Bortolami M; Scipione L; Costi R; Rivara S; Scalvini L; Mor M; Ferrara FF; Pavoni E; Roscilli G; Cassinelli G; Milazzo FM; Battistuzzi G; Di Santo R; Giannini G
    J Med Chem; 2018 Aug; 61(15):6918-6936. PubMed ID: 30010344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity.
    Messore A; Madia VN; Pescatori L; Saccoliti F; Tudino V; De Leo A; Bortolami M; De Vita D; Scipione L; Pepi F; Costi R; Rivara S; Scalvini L; Mor M; Ferrara FF; Pavoni E; Roscilli G; Cassinelli G; Milazzo FM; Battistuzzi G; Di Santo R; Giannini G
    J Med Chem; 2018 Dec; 61(23):10834-10859. PubMed ID: 30412404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydrithieno[2,3-b]naphto-4,9-dione analogues as anticancer agents: Synthesis and in cell pharmacological studies.
    Bertamino A; Musella S; Di Sarno V; Ostacolo C; Manfra M; Vanacore D; Stiuso P; Novellino E; Campiglia P; Gomez-Monterrey IM
    Eur J Med Chem; 2015 Sep; 102():106-14. PubMed ID: 26253231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIα and Akt pathway inhibitor, and evaluation of its anti-melanoma activity.
    Karelia DN; Sk UH; Singh P; Gowda ASP; Pandey MK; Ramisetti SR; Amin S; Sharma AK
    Eur J Med Chem; 2017 Jul; 135():282-295. PubMed ID: 28458134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.